ENTA RSI Chart
Last 7 days
-14.4%
Last 30 days
-9.9%
Last 90 days
8.7%
Trailing 12 Months
-63.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 81.2M | 80.6M | 79.2M | 73.6M |
2022 | 91.6M | 89.4M | 86.2M | 82.1M |
2021 | 94.2M | 97.1M | 97.1M | 93.0M |
2020 | 175.9M | 150.2M | 122.5M | 101.6M |
2019 | 234.0M | 221.1M | 205.2M | 187.9M |
2018 | 165.6M | 215.3M | 206.6M | 238.4M |
2017 | 46.2M | 39.7M | 102.8M | 130.5M |
2016 | 87.5M | 89.8M | 88.3M | 50.2M |
2015 | 179.6M | 149.1M | 160.9M | 131.8M |
2014 | 6.1M | 46.5M | 47.7M | 124.3M |
2013 | 36.9M | 34.5M | 32.1M | 5.1M |
2012 | 0 | 0 | 41.7M | 39.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 26, 2024 | gardiner nathaniel s. | acquired | 46,631 | 8.99 | 5,187 | chief legal officer |
Feb 12, 2024 | luu brendan | sold (taxes) | -12,074 | 12.41 | -973 | chief business officer |
Feb 12, 2024 | kieffer tara lynn | acquired | - | - | 3,320 | chief product strategy officer |
Feb 12, 2024 | luly jay r. | sold (taxes) | -19,657 | 12.41 | -1,584 | president and ceo |
Feb 12, 2024 | mellett paul j | sold (taxes) | -12,074 | 12.41 | -973 | chief fin. & admin officer |
Feb 12, 2024 | gardiner nathaniel s. | sold (taxes) | -12,074 | 12.41 | -973 | chief legal officer |
Feb 12, 2024 | luly jay r. | acquired | - | - | 5,400 | president and ceo |
Feb 12, 2024 | luu brendan | acquired | - | - | 3,320 | chief business officer |
Feb 12, 2024 | or yat sun | acquired | - | - | 3,680 | chief scientific officer |
Feb 12, 2024 | gardiner nathaniel s. | acquired | - | - | 3,320 | chief legal officer |
Which funds bought or sold ENTA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 22, 2024 | MetLife Investment Management, LLC | unchanged | - | -18,199 | 97,299 | -% |
Apr 18, 2024 | Allspring Global Investments Holdings, LLC | sold off | -100 | -4,742 | - | -% |
Apr 18, 2024 | Diversified Trust Co | sold off | -100 | -159,029 | - | -% |
Apr 17, 2024 | Hennion & Walsh Asset Management, Inc. | reduced | -13.09 | 90,793 | 239,010 | 0.01% |
Apr 16, 2024 | TOTH FINANCIAL ADVISORY CORP | new | - | 1,310 | 1,310 | -% |
Apr 05, 2024 | GAMMA Investing LLC | unchanged | - | 229 | 751 | -% |
Apr 05, 2024 | CWM, LLC | reduced | -11.04 | 2,000 | 5,000 | -% |
Apr 03, 2024 | Versant Capital Management, Inc | unchanged | - | 556 | 1,205 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -79.48 | -9,637 | 2,014 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 8.03 | -1,668,480 | 16,879,500 | -% |
Unveiling Enanta Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Enanta Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.74 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.4B | 1.8B | -41.79 | 10.06 | ||||
BMRN | 17.4B | 2.4B | 103.61 | 7.18 | ||||
INCY | 11.6B | 3.7B | 19.4 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 5.9B | 396.6M | -11.11 | 14.81 | ||||
BBIO | 4.5B | - | -6.85 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.47 | 12.79 | ||||
ARWR | 2.9B | 240.7M | -9.93 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.01 | 3.8 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.31 | 4.36 | ||||
NVAX | 587.8M | 983.7M | -1.08 | 0.6 | ||||
CRBP | 396.0M | 881.7K | -8.88 | 466.16 | ||||
INO | 242.4M | 4.9M | -1.79 | 49.8 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Enanta Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -4.9% | 18,003,000 | 18,932,000 | 18,892,000 | 17,795,000 | 23,585,000 | 20,317,000 | 19,479,000 | 18,716,000 | 27,648,000 | 23,575,000 | 21,624,000 | 20,132,000 | 31,743,000 | 23,631,000 | 18,653,000 | 27,619,000 | 52,570,000 | 51,313,000 | 44,367,000 | 39,631,000 | 69,886,000 |
Costs and Expenses | 5.9% | 52,889,000 | 49,962,000 | 55,605,000 | 57,246,000 | 53,598,000 | 47,365,000 | 52,019,000 | 52,563,000 | 58,057,000 | 57,302,000 | 55,471,000 | 49,832,000 | 44,042,000 | 43,414,000 | 41,505,000 | 39,494,000 | 39,699,000 | 44,882,000 | 40,612,000 | 40,935,000 | 42,030,000 |
S&GA Expenses | 19.7% | 16,518,000 | 13,795,000 | 12,618,000 | 13,778,000 | 12,696,000 | 12,569,000 | 12,929,000 | 10,476,000 | 9,508,000 | 8,356,000 | 8,477,000 | 8,326,000 | 7,377,000 | 6,728,000 | 6,823,000 | 6,884,000 | 6,921,000 | 6,163,000 | 6,151,000 | 6,780,000 | 7,152,000 |
R&D Expenses | 0.6% | 36,371,000 | 36,167,000 | 42,987,000 | 43,468,000 | 40,902,000 | 34,796,000 | 39,090,000 | 42,087,000 | 48,549,000 | 48,946,000 | 46,994,000 | 41,506,000 | 36,665,000 | 36,686,000 | 34,682,000 | 32,610,000 | 32,778,000 | 38,719,000 | 34,461,000 | 34,155,000 | 34,878,000 |
EBITDA Margin | -8.8% | -1.70 | -1.56 | -1.56 | -1.51 | -1.44 | -1.38 | -1.41 | -1.39 | -1.32 | -1.07 | -0.92 | -0.82 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 9.2% | 3,441,000 | 3,151,000 | 1,997,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | 55.9% | -622,000 | -1,410,000 | 4,221,000 | 44,000 | -34,000 | 32,000 | -447,000 | - | -36,000 | -15,905,000 | -9,384,000 | 7,110,000 | -3,294,000 | 10,707,000 | -7,142,000 | -3,920,000 | 1,504,000 | -486,000 | -866,000 | -3,204,000 | 3,730,000 |
Earnings Before Taxes | -15.3% | -34,029,000 | -29,517,000 | -34,844,000 | -37,614,000 | -29,020,000 | -26,316,000 | -32,147,000 | -33,592,000 | -30,151,000 | -33,394,000 | -33,408,000 | -29,155,000 | -11,622,000 | -18,634,000 | -21,407,000 | -9,925,000 | 14,947,000 | 8,705,000 | 6,170,000 | 941,000 | 29,741,000 |
EBT Margin | -11.7% | -1.85 | -1.65 | -1.59 | -1.54 | -1.47 | -1.42 | -1.45 | -1.43 | -1.36 | -1.11 | -0.96 | -0.86 | - | - | - | - | - | - | - | - | - |
Net Income | -18.9% | -33,407,000 | -28,107,000 | -39,065,000 | -37,658,000 | -28,986,000 | -26,348,000 | -31,700,000 | -33,592,000 | -30,115,000 | -24,599,000 | -24,024,000 | -22,045,000 | -8,328,000 | -29,341,000 | -14,265,000 | -6,005,000 | 13,443,000 | 9,191,000 | 7,036,000 | 4,145,000 | 26,011,000 |
Net Income Margin | -11.1% | -1.88 | -1.69 | -1.64 | -1.54 | -1.47 | -1.41 | -1.34 | -1.23 | -1.08 | -0.81 | -0.86 | -0.79 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -12.2% | -25,775,000 | -22,970,000 | -34,279,000 | -16,166,000 | -38,797,000 | -16,971,000 | -29,853,000 | -26,449,000 | -13,634,000 | -21,054,000 | -29,905,000 | -4,709,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -7.3% | 428 | 462 | 495 | 326 | 348 | 375 | 385 | 407 | 441 | 439 | 450 | 468 | 481 | 486 | 512 | 514 | 511 | 490 | 473 | 462 | 454 |
Current Assets | -7.7% | 390 | 423 | 448 | 271 | 284 | 312 | 313 | 342 | 327 | 319 | 321 | 428 | 446 | 437 | 413 | 403 | 441 | 402 | 451 | 424 | 423 |
Cash Equivalents | -53.2% | 40.00 | 85.00 | 95.00 | 73.00 | 42.00 | 44.00 | 28.00 | 41.00 | 99.00 | 57.00 | 5.00 | 77.00 | 55.00 | 87.00 | 100 | 74.00 | 28.00 | 51.00 | 94.00 | 106 | 74.00 |
Net PPE | 1.7% | 12.00 | 12.00 | 12.00 | 11.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 | 6.00 | 7.00 | 7.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 11.00 | 9.00 |
Liabilities | -3.6% | 237 | 246 | 257 | 57.00 | 47.00 | 54.00 | 47.00 | 48.00 | 56.00 | 39.00 | 33.00 | 32.00 | 29.00 | 31.00 | 31.00 | 28.00 | 29.00 | 27.00 | 25.00 | 25.00 | 27.00 |
Current Liabilities | -0.6% | 62.00 | 63.00 | 68.00 | 32.00 | 23.00 | 30.00 | 23.00 | 31.00 | 38.00 | 36.00 | 29.00 | 27.00 | 23.00 | 24.00 | 24.00 | 20.00 | 19.00 | 23.00 | 21.00 | 20.00 | 23.00 |
Shareholder's Equity | -11.5% | 192 | 217 | 238 | 269 | 301 | 321 | 338 | 359 | 384 | 399 | 418 | 436 | 452 | 456 | 481 | 486 | 482 | 462 | 448 | 436 | 427 |
Retained Earnings | -16.1% | -240 | -206 | -178 | -139 | -102 | -73.18 | -46.83 | -15.13 | 18.00 | 49.00 | 73.00 | 97.00 | 119 | 128 | 157 | 171 | 177 | 164 | 155 | 148 | 143 |
Additional Paid-In Capital | 1.9% | 433 | 425 | 418 | 411 | 405 | 398 | 388 | 377 | 367 | 351 | 345 | 339 | 332 | 327 | 322 | 314 | 305 | 298 | 293 | 289 | 284 |
Shares Outstanding | 0.5% | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 800 | - | - | - | 1,262 | - | - | - | 865 | - | - | - | 754 | - | - | - | 1,408 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -15.7% | -24,988 | -21,602 | -32,128 | -13,783 | -35,641 | -15,534 | -29,602 | -26,375 | -13,271 | -21,021 | -29,506 | -4,579 | -14,890 | -15,461 | -4,488 | 14,674 | 12,363 | 8,545 | 2,533 | 30,086 | 30,254 |
Share Based Compensation | 20.6% | 8,099 | 6,716 | 6,998 | 7,363 | 7,139 | 6,833 | 7,603 | 6,471 | 6,062 | 5,353 | 5,475 | 5,280 | 4,883 | 4,745 | 4,754 | 4,978 | 5,098 | 4,512 | 4,164 | 4,707 | 5,843 |
Cashflow From Investing | -210.8% | -13,117 | 11,836 | -145,748 | 46,765 | 33,569 | 28,231 | 16,220 | -35,055 | 45,501 | 72,683 | -43,705 | 25,458 | -17,445 | 2,504 | 26,779 | 27,748 | -37,201 | -52,208 | -14,847 | 1,322 | -20,931 |
Cashflow From Financing | -31856.5% | -7,350 | -23.00 | 199,875 | -2,027 | 301 | 2,930 | 4,120 | 3,351 | 9,632 | 943 | 686 | 1,152 | 299 | 233 | 3,226 | 4,358 | 1,166 | 687 | 490 | 257 | 1,140 |
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Total revenue | $ 18,003 | $ 23,585 |
Operating expenses: | ||
Research and development | 36,371 | 40,902 |
General and administrative | 16,518 | 12,696 |
Total operating expenses | 52,889 | 53,598 |
Loss from operations | (34,886) | (30,013) |
Other income (expense): | ||
Interest expense | (3,441) | 0 |
Interest and investment income, net | 4,298 | 993 |
Total other income, net | 857 | 993 |
Loss before income taxes | (34,029) | (29,020) |
Income tax benefit | 622 | 34 |
Net loss | $ (33,407) | $ (28,986) |
Net loss per share: | ||
Basic | $ (1.58) | $ (1.39) |
Diluted | $ (1.58) | $ (1.39) |
Weighted average shares outstanding: | ||
Basic | 21,088 | 20,816 |
Diluted | 21,088 | 20,816 |
Royalty [Member] | ||
Total revenue | $ 18,003 | $ 22,585 |
License [Member] | ||
Total revenue | $ 0 | $ 1,000 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|---|
Current assets: | |||
Cash and cash equivalents | $ 39,933 | $ 85,388 | |
Short-term marketable securities | 297,218 | 284,522 | |
Accounts receivable | 8,173 | 8,614 | |
Prepaid expenses and other current assets | 13,245 | 13,263 | |
Income tax receivable | 31,734 | 31,004 | |
Total current assets | 390,303 | 422,791 | |
Property and equipment, net | 12,119 | 11,919 | |
Operating lease, right-of-use assets | 21,344 | 22,794 | |
Restricted cash | 3,968 | 3,968 | |
Other long-term assets | 765 | 803 | |
Total assets | 428,499 | 462,275 | |
Current liabilities: | |||
Accounts payable | 9,326 | 4,097 | |
Accrued expenses and other current liabilities | 11,603 | 18,339 | |
Liability related to the sale of future royalties | 36,512 | 35,076 | |
Operating lease liabilities | 4,966 | 5,275 | |
Total current liabilities | 62,407 | 62,787 | |
Liability related to the sale of future royalties, net of current portion | 151,612 | 159,429 | |
Operating lease liabilities, net of current portion | 20,524 | 21,238 | |
Series 1 nonconvertible preferred stock | 1,423 | 1,423 | |
Other long-term liabilities | 649 | 663 | |
Total liabilities | 236,615 | 245,540 | |
Commitments and contingencies (Note 11) | |||
Stockholders' equity: | |||
Common stock; $0.01 par value per share, 100,000 shares authorized; 21,156 and 21,059 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively | 212 | 211 | |
Additional paid-in capital | 432,608 | 424,693 | |
Accumulated other comprehensive loss | (534) | (1,174) | |
Accumulated deficit | (240,402) | (206,995) | |
Total stockholders' equity | 191,884 | 216,735 | $ 300,837 |
Total liabilities and stockholders' equity | $ 428,499 | $ 462,275 |
 | Dr. Jay R. Luly Ph.D. |
---|---|
 | enanta.com |
 | Biotechnology |
 | 160 |